

BB-775
TXR-2106

MEMORANDUM

002106

Date: June 10, 1981

Subject: EPA File Symbol - 2217-AUG
Trimec 24 Weed and Feed:
Caswell # _____

From: Deloris F. Graham *DFG*
FHB/TSS

6/10/81
E 6/19/81

To: Richard Mountfort
Product Manager (23)

Applicant: FBI/Gordon Corporation
300 South Third Street
P.O. Box 2276
Kansas City, Kansas 66110

Active Ingredient:

2,4-Dichlorophenoxyacetic acid.....0.5820%

2-(2-Methyl-4-chlorophenoxy) propionic acid.....0.2448%

Dicamba (3,6-dichloro-o-anisic acid)0.0516%

Inert Ingredient.....99.1216%

Background: Acute Oral, Acute Dermal, Eye Irritation and Skin Irritation studies were submitted. The studies were conducted by Stillmeadow, Inc. Data under accession numbers 245103, 245104, 245105 and 245106. Combined "cite-all" and alternate method of support.

Recommendation:

- 1) FHB/TSS finds these data acceptable to support conditional registration of this product.

Label:

- (1) The appropriate signal word is CAUTION.

174

002106

(2) The statement "Keep out of lakes, streams, and ponds" must be revised to read "Do not apply directly to water."

Review:

(1) Acute Oral Toxicity Study: Stillmeadow, Inc., Project #2098-81; April 3, 1981.

Procedure: 5M and 5F rats received a 5050 mg/kg dose of the test material orally. Observations made at least 3 times on the day of treatment and at least twice daily thereafter for 14 days. Necropsies were performed on all animals.

Results: No mortalities. Dilated pupils, diarrhea, and polyuria present in first 3 hours after treatment. No abnormalities at necropsy. LD50 greater than 5050mg/kg.

Study Classification: Core Guideline Data.

Toxicity Category: IV - CAUTION

(2) Acute Dermal Toxicity Study: Stillmeadow, Inc.; Project # 2089-81; April 10, 1981.

Procedure: A sham control group consisting of 5M and 5F and treated group consisting of 5M and 5F dosed at 2010 mg/kg were used. The test material was applied to abraded skin sites and placed under occlusive wrap for 24 hour exposure. Observations were made at 1/2, 3, 6, 24 hours after treatment then daily thereafter through 14 days. Necropsy on all animals.

Results: No Mortalities. No Toxicologic effects observed. LD50 greater than 2010 mg/kg.

Study Classification: Core Guideline Data

Toxicity Category: III - CAUTION

(3) Eye Irritation Study: Stillmeadow, Inc.; Project #2090-81; March 20, 1981.

Procedure: 9 New Zealand white rabbits received a 100 mg dose in one eye each. The animals were divided into two groups. Group I consisted of 6 animals with treated unwashed eyes and Group II consisted of 3 animals with treated washed eyes. Observations were made at 1, 24, 38 and 72 hours and 4 and 7 days after treatment.

Results: In Group I at 24 hours, no corneal opacity, 4/6 animals had iris irritation (2/6=5, 2/6=10), 6/6 conjunctive redness (4/6=2, 2/6=3), chemosis (1/6=2, 4/6=3, 1/6=4), and discharge (4/6=2, 2/6=3). At day 7 no irritation.

2

002106

In Group II at 24 hours, no corneal opacity; 2/3 animals had iris irritation (1/3=5, 1/3=10); 3/3 conjunctive redness (2/3=2, 1/3=3); chemosis (1/3=2, 1/3=3, 1/3=4), discharge (1/3=1, 1/3=2, 1/3=3). At Day 7 no irritation.

Stippling also present in Group I and Group II.

Study Classification: Core Guideline Data

Toxicity Category: III - CAUTION

(4) Dermal Irritation Study: Stillmeadow, Inc.; Project # 2091-81; March 27, 1981.

Procedure: 3M and 3F New Zealand white rabbits received a 0.5g dose at 2 abraded and 2 intact skin sites per animal. Observations were made at 24 and 72 hours.

Results: Slight to well defined erythema and slight edema at both intact and abraded skin sites at 24 hours. Slight erythema and edema at 72 hours. Primary Irritation Score was 1.25.

Study Classification: Core Guideline Data.

Toxicity Category: IV - CAUTION

3

Mecoprop Scientific Reviews

Page 4 is not included in this copy.

Pages _____ through _____ are not included in this copy.

The material not included contains the following type of information:

- ☐ Identity of product inert ingredients
 - ☐ Identity of product impurities
 - ☐ Description of the product manufacturing process
 - ☐ Description of product quality control procedures
 - ☐ Identity of the source of product ingredients
 - ☐ Sales or other commercial/financial information
 - ☒ A draft product label
 - ☐ The product confidential statement of formula
 - ☐ Information about a pending registration action
 - ☐ FIFRA registration data
 - ☐ The document is a duplicate of page(s) _____
 - ☐ The document is not responsive to the request
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
